I-BET151 inhibits expression of RANKL, OPG, MMP3 and MMP9 in ankylosing spondylitis in vivo and in vitro

JIANPING FAN¹,², JIAN ZHAO¹, JIE SHAO¹, XIANZHAO WEI¹, XIAODONG ZHU¹ and MING LI¹

¹Department of Orthopedics, Changhai Hospital, Second Military Medical University, Shanghai 200433; ²Department of Orthopedics, Handan 285 Hospital, Handan, Hebei 056000, P.R. China

Received March 21, 2017; Accepted July 26, 2017

DOI: 10.3892/etm.2017.5032

Abstract. Ankylosing spondylitis (AS) is characterized by osteoclastogenesis and inflammatory bone resorption. The present study aimed to investigate the effect of bromodomain and extra-terminal domain (BET) protein inhibitor I-BET151 on AS process. A total of 38 AS Chinese patients were recruited and a further 38 sex- and age-matched healthy participants were selected as control. The Bath AS Function Index and Bath AS Disease Activity Index were assessed in AS patients and levels of erythrocyte sedimentation rate and C-reactive protein were measured in AS and healthy groups. Serum from AS patients was used to induce MG63 osteoblasts and BET inhibitor I-BET151 at concentrations of 50, 100 and 200 ng/ml for treatment of the cells. A HLA-B27/ß2m transgenic AS Lewis rat model was established and treated with 30 mg/kg I-BET151 for 5 weeks. Levels of receptor activator of nuclear factor-κB ligand (RANKL), osteoprotegerin (OPG), matrix metalloproteinase (MMP)3, and MMP9 were measured using ELISA in vivo and additionally detected with western blotting and polymerase chain reaction in vitro. The levels of RANKL, OPG, MMP3 and MMP9 were upregulated in AS serum, AS serum treated MG63 cells and HLA-B27/ß2m transgenic AS rats. Conversely, levels of RANKL, OPG, MMP3 and MMP9 were significantly inhibited in cells or animals treated with I-BET151. Overall, the results of the present study demonstrated that BET inhibitor I-BET151 suppresses levels of RANKL, OPG, MMP3 and MMP9 in AS in vivo and in vitro. I-BET151 may exhibit the potential to be used as a therapeutic in the treatment of AS patients.

Introduction

Ankylosing spondylitis (AS) is a kind of chronic inflammatory disease which occurs in enthuses and spine with 2 basic characteristics, osteoporosis and ankylosis of axial joints (1). Studies show that elevated levels of inflammatory cytokines and matrix metalloproteinases (MMPs) are observed in AS patients, such as tumour necrosis factors, interleukins, MMP2, MMP3 and MMP8 (2-4). Recently, signal pathway of receptor activator of nuclear factor-κB ligand (RANKL)/osteoprotegerin (OPG) attracted scholars' attention. It was reported that increased RANKL could mediate osteoclastogenesis in AS patients or animal models (3). Moreover, bone resorption of skeleton could be protected by secreting OPG via osteoblasts. As reported, the balance of OPG and RANKL, as known as OPG/RANKL ratio, is important for maintaining normal bone metabolism. It is widely known that the OPG/RANKL ratio increases during the differentiation process of osteoblasts. In addition, upregulation of OPG/RANKL ratio has been well detected in AS patients (4-6).

Bromodomain and extra-terminal domain (BET) proteins is a ‘histone reading protein’ class and epigenetic-related proteins (3-5,7). It was reported that BET proteins played important roles in inflammatory bone resorption and osteoclastogenesis (3-5). In addition, BET bromodomain inhibitor could reduce osteosarcoma cell proliferation and osteoblastic differentiation (8-10). It was also reported that I-BET151, a BET bromodomain inhibitor, could regulate inflammatory factors in process of inflammatory diseases (7). However, there was no report focusing on the effects of BET inhibitors on the expression of OPG/RANKL system related factors in AS.

This study was designed to investigate the effect of I-BET151, a BET inhibitor, on the process of AS both in vivo and in vitro by AS cell model and animal model. The expression of RANKL, OPG, and MMPs including MMP3 and MMP9 in AS patients and animal serum as well as cells were detected.

Materials and methods

AS patients. A total of 38 AS Chinese patients were recruited from outpatient clinics at the Department of Orthopedics, Changhai Hospital, Second Military Medical University (Shanghai, China). All patients fulfilled the modified AS criteria of New York classification (4) and another 38 sex- and age-matched...
healthy people were included in the present study as a healthy control. The Bath AS Function Index (BASFI, 0 = none and 10 = worst) and the Bath AS Disease Activity Index (BASDAI, 0 = none and 10 = worst) of AS patients were assessed (11,12). The participants demographic and disease characteristics were showed in Table I. Two inflammation markers including erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels in serum from participants were detected. All the experiments performed in the present study followed the approval of the Ethics Committee of Changhai Hospital and written informed consents were obtained from all participants.

**Cells and treatment.** A density of 2x10^5 cells/ml of human MG63 osteoblasts (American Type Culture Collection, Rockville, MD, USA) were incubated in 6-well plates with DMEM (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) supplemented with 1% penicillin-streptomycin and 10% FBS (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) at 37°C with 5% CO₂ for 24 h. Then cells were subjected into 250 µl of serum from AS patients in DMEM for another 48 h to induce AS cell model (4). For inhibition of RANKL/OPG system, MG63 cells were pretreated with 50, 100 and 200 ng/ml BET inhibitor I-BET151 (GlaxoSmithKline, Brentford, UK) for 2 h before AS serum addition (13,14). Each experiment was performed in triplicate.

**AS animal model.** HLA-B27/β2 m transgenic AS Lewis rat model was constructed as previously described (15,16). A total of 20 AS rats were constructed and all animals (including normal Lewis rats, n=10) were housed in standard conditions under a 12-h light/dark cycle with free access to food and water. For I-BET151 treatment, 20 transgenic rats were intraperitoneally administrated with 30 mg/kg of I-BET151 (n=10; GlaxoSmithKline, London, UK) and 48 h later, all animals were anesthetized and 0.5 ml of blood samples were collected before sacrifice. Animal procedures were performed according to Institutional Standards for Human Care and Use of Laboratory Animals.

**ELISA assay.** Blood samples collected from patients and animals were put into tubes and centrifuged at 1000 x g for 10 min and supernatants were collected for ELISA assay for RANKL, OPG, MMP3, and MMP9 (R&D Systems, Inc., Minneapolis, MN, USA). ELISA reader was used for absorption at 450 nm with batched controls.

**Cellular RNA isolation and qPCR.** Cellular RNA was extracted and the first-strand cDNA was synthesized for mRNA expression levels detection using ABI 7500 Real-Time PCR software (Applied Biosystems, Carlsbad, CA, USA) by a SYBR-Green PCR Master mix Kit (Applied Biosystems) according: denaturation at 94°C for 4 min, 40 cycles of desaturating at 94°C for 40 sec, annealing at 60°C for 30 sec and elongation at 70°C for 20 sec. Relative mRNA expression levels were calculated to reference GAPDH gene using the 2^(-ΔΔCq) method.

**Western immunoblotting analysis.** Cell lysates were prepared and separated using SDS-PAGE (10%). Then proteins were transferred to PVDF membrane. After being blocked with BSA, membranes were then incubated with primary antibodies anti-RANKL (1:1,000; BD Transduction Laboratories, San Jose, CA, USA), -OPG (1:1,000; Millipore Corp., Billerica, MA, USA), MMP3 (1:1,500; Millipore Corp.), MMP9 (1:1,000; BD Transduction Laboratories), GAPDH (1:2,000; BD Transduction Laboratories) at 4°C overnight followed by incubation with secondary antibodies for 1 h and subject to ECL reagents (Amersham Pharmacia Biotech, Inc., Piscataway, NJ, USA) for visualization of western blots.

**Statistical analysis.** Each experiment was performed in triplicate, and all data are showed as the mean ± standard deviation. Differences between groups and among groups were assessed using SPSS by analysis of Student's t-test or ANOVA, respectively. P<0.05 was considered to indicate a statistically significant difference.

### Results

**Expression of RANKL, OPG, MMP3, MMP9 in AS patients.** The demographic and disease characteristics of the 76 participants are listed in Table I. Data showed that there was a higher AS accordance in man than that of women, and a 33 AS patients among the 38 patients were HLA-B27 positive (86.8%). Expression of RANKL, OPG, MMP3, and MMP9 in different groups was detected by ELISA and showed in Fig. 1. ELISA assay showed that the expression of RANKL, MMP3, and MMP9 was significantly upregulated in AS serum than those in healthy subjects, P<0.05. However, no significant difference was observed in OPG in AS patients compared with the healthy control, P>0.05.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>AS patients</th>
<th>Healthy controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male/female, no. (%)</td>
<td>30/8 (78.9)</td>
<td>30/8 (78.9)</td>
</tr>
<tr>
<td>Age, years</td>
<td>31.4±6.0</td>
<td>32.3±5.6</td>
</tr>
<tr>
<td>Symptom duration, years</td>
<td>3.8±5.4</td>
<td>NA</td>
</tr>
<tr>
<td>HLA-B27 positive, no. (%)</td>
<td>33 (86.8)</td>
<td>NA</td>
</tr>
<tr>
<td>BASFI</td>
<td>3.0±3.1</td>
<td>NA</td>
</tr>
<tr>
<td>BASDAI</td>
<td>3.8±3.5</td>
<td>NA</td>
</tr>
<tr>
<td>CRP, mg/l</td>
<td>22.0±21.8</td>
<td>1.95±0.84</td>
</tr>
<tr>
<td>ESR, mm/h</td>
<td>23.9±18.6</td>
<td>4.63±1.25</td>
</tr>
</tbody>
</table>

**AS, ankylosing spondylitis; HLA-B27, human leukocyte antigen B27; BASDAI, Bath AS Disease Activity Index; BASFI, Bath AS Functional Index; CRP, C-reactive protein (reference range, <6 mg/l); ESR, erythrocyte sedimentation rate (reference range, male <15 mm/h; female <20 mm/h); NA, not applicable.**

### I-BET151 inhibited AS serum induced expression of RANKL, OPG, MMP3, MMP9 in MG63 cell model.

We treated MG63 cells with AS serum to induce the AS cell model in vitro. The expression of RANKL/OPG system factors RANKL, OPG, MMP3, and MMP9 mRNA and proteins were detected. The

**Table I. The participants demographic and disease characteristics of the study subjects.**
results showed that both the mRNA and proteins of RANKL, OPG, MMP3, and MMP9 were significantly upregulated in AS serum induced MG63 cells compared with the control, P<0.01 (Fig. 2A-D). However, MG63 cells pretreated with I-BET151 showed significantly inhibitory effects on expression of RANKL, OPG, MMP3, and MMP9 in both mRNAs
and proteins levels compared with MG63 AS model, with a dose-dependent manner. The expression of RANKL, OPG, MMP3, and MMP9 mRNAs and proteins showed the lowest expression levels in MG63 cells pretreated with 200 ng/ml I-BET151 than those of 50 and 100 ng/ml I-BET151, P<0.05. These results demonstrated that I-BET151 suppressed the expression of RANKL/OPG system.

**I-BET151 suppressed expression of RANKL, OPG, MMP3, and MMP9 in AS rat model.** We established the rat AS model using HLA-B27/β2 m transgenic Lewis rats. Levels of RANKL, OPG, MMP3, and MMP9 in rat serum were determined. The results showed that RANKL, OPG, MMP3, and MMP9 were upregulated in AS rats compared with the control rats, P<0.05 (Fig. 3). On the contrary, AS rats treated with 30 mg/kg of I-BET151 for 5 weeks showed significant inhibitory effects on levels of RANKL, OPG, MMP3, and MMP9 compared with the model, P<0.05. These data demonstrated that I-BET151 could inhibit AS-induced expression of RANKL, OPG, MMP3, and MMP9 in AS rats.

**Discussion**

Previous reports have demonstrated the upregulation of MMPs, OPG, and RANKL in AS patients (2,3,6). However, to our best knowledge, there is no study focusing on effects of BET and its inhibitors in AS up to now. In the present study, we demonstrated the inhibitory effects of a BET inhibitor, I-BET151, on expression of MMPs, OPG, and RANKL in AS both in vivo and in vitro.

First we detected the expression of MMPs, OPG, and RANKL in AS patients as well as healthy control. Results showed that in AS patients all levels of above proteins increased. This result was in consistent with other studies. It was reported that RANKL and MMPs are inflammatory factors related to arthritis category (6). Association between RANKL expression and bone destruction was confirmed in inflammatory joints using animal model and the inflammatory cytokines of RANKL/OPG axis showed essential roles in AS process (4,17). In addition, MMPs upregulation, especially for MMP3, has been detected in AS serum and thus could be used as biomarkers for AS diagnosis (6,18).

Then we used AS serum to induce AS model in vitro and established AS rats model in vivo. Then we determined expression of MMPs, OPG, and RANKL both in vitro and in vivo. Results showed that all OPG, RANKL, MMP3 and MMP9 were significantly upregulated in AS serum treated MG63 cells as well as in HLA-B27/β2 m transgenic Lewis rats. However, when treated with I-BET-151, all these effects induced by AS were significantly inhibited.

The upregulation of RANKL and conflicting dysregulation of OPG in AS serum have been reported in numerous studies (6). Both the up-, down-, and no-regulation of OPG had been reported in AS studies. However, effect of BET inhibitor in AS is unknown.

The important role of BET bromodomain signaling in osteosarcoma is widely accepted, and the inhibition of it can suppresses growth of osteosarcoma tumour (8). Moreover, inhibition of BET protein suppresses osteoblastogenesis as well as osteoclast differentiation (19-21).

In the present study, we firstly demonstrated that I-BET151, a BET inhibitor, could suppress the upregulation of RANKL, OPG, MMP3, and MMP9 in AS serum treated MG63 cells and AS rats, suggesting the potential of using...
I-BET151 as a therapeutic strategy for AS both in vitro and in vivo.

In conclusion, In summary, we demonstrated the upregulation of RANKL, OPG, MMP3, and MMP9 in AS in vitro and in vivo. The administration of BET inhibitor I-BET151 suppressed the expression of RANKL, OPG, MMP3, and MMP9 in AS in a dose-dependent manner. We concluded that I-BET151 might be used as a potential therapeutic strategy for AS patients after more future clinical studies.

References


